Literature DB >> 26574574

Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to d-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation.

Neha Singh1, Hara Prasad Pati1, Seema Tyagi1, Ashish Datt Upadhyay2, Renu Saxena1.   

Abstract

INTRODUCTION: Disseminated intravascular coagulation (DIC) is a thrombohemorrhagic disorder characterized by hyperactivation of coagulation and secondary fibrinolysis. AIM: The primary aim of this prospective study was to evaluate and compare the diagnostic performance of fibrin monomer (FM) and d-dimer (DD) for the preemptive diagnosis of DIC in the early stages.
MATERIALS AND METHODS: The patients were categorized into 3 groups: overt DIC, nonovert DIC, and non-DIC based on the International Society of Thrombosis and Hemostasis scoring for overt DIC and the modified nonovert-DIC criteria. Coagulation tests were performed on freshly obtained plasma. Quantitative determination of FM and DD was done by immunoturbidimetric assay.
RESULTS: Median DD and FM levels in patients with overt DIC were significantly higher in comparison to the other 2 groups. Interestingly, unlike DD, the difference in FM levels was also found to be statistically significant between patients with nonovert DIC and non-DIC patients ( P = .0001). At receiver-operator characteristic curve-generated cutoff values, FM had higher specificity and negative predictive value than DD for predicting onset of overt DIC. Multivariate analysis showed that only FM was as an independent predictive factor useful in differentiating patients with overt DIC from non-DIC patients (odds ratio [OR]: 43.3; confidence interval [CI] 4.61-406.68; P value = .001) as well as in distinguishing nonovert DIC from non-DIC patients (OR:18.3; CI 3.45-97.19; P value = .001).
CONCLUSION: Fibrin monomer is a better indicator than DD in distinguishing patients with overt and nonovert DIC from non-DIC patients, raising the possibility for its diagnostic utility as a marker for impending overt DIC, aiding in early diagnosis and prompt therapeutic intervention.

Entities:  

Keywords:  d-Dimer; nonovert DIC; overt DIC; soluble fibrin monomer complexes

Mesh:

Substances:

Year:  2015        PMID: 26574574     DOI: 10.1177/1076029615615959

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

1.  Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.

Authors:  José Miguel Rivera-Caravaca; Vanessa Roldán; Marta Romera; María Asunción Esteve-Pastor; Mariano Valdés; Gregory Y H Lip; Vicente Vicente; Francisco Marín
Journal:  J Gen Intern Med       Date:  2018-03-22       Impact factor: 5.128

2.  D-dimer testing in clinical practice in the era of COVID-19.

Authors:  Claire Auditeau; Lina Khider; Benjamin Planquette; Olivier Sanchez; David M Smadja; Nicolas Gendron
Journal:  Res Pract Thromb Haemost       Date:  2022-05-25

3.  Ability of Fibrin Monomers to Predict Progressive Hemorrhagic Injury in Patients with Severe Traumatic Brain Injury.

Authors:  Pierre Esnault; Quentin Mathais; Erwan D'Aranda; Ambroise Montcriol; Mickaël Cardinale; Pierre-Julien Cungi; Philippe Goutorbe; Christophe Joubert; Arnaud Dagain; Eric Meaudre
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

4.  Soluble fibrin monomer complex is associated with cardio- and cerebrovascular events in patients with heart failure.

Authors:  Akiomi Yoshihisa; Yu Sato; Yusuke Kimishima; Yasuhiro Ichijo; Tetsuro Yokokawa; Tomofumi Misaka; Takamasa Sato; Masayoshi Oikawa; Atsushi Kobayashi; Kazuhiko Nakazato; Yasuchika Takeishi
Journal:  Int J Cardiol Heart Vasc       Date:  2020-12-24

5.  Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.

Authors:  Chrysoula Papageorgiou; Georges Jourdi; Eusebe Adjambri; Amanda Walborn; Priya Patel; Jawed Fareed; Ismail Elalamy; Debra Hoppensteadt; Grigoris T Gerotziafas
Journal:  Clin Appl Thromb Hemost       Date:  2018-10-08       Impact factor: 2.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.